ONK is also developing ONKT104, a dual-targeted CAR-NK product targeting CLEC12A (also known as CLL-1) utilising a humanised ScFv. CLEC12A is strongly expressed by blasts in the majority of acute ...

Fintel reports that on December 18, 2024, Wells Fargo downgraded their outlook for ONEOK (XTRA:ONK) from Overweight to Equal-Weight. As of December 3, 2024, the average one-year price target for ...